Compare Adaptive Biotechnologies Corp (ADPT) vs Allstate Corp (ALL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Allstate Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Allstate Corp trades at $250.53 (market cap $63.94B). The key difference: Allstate Corp is far larger — about 19.2× Adaptive Biotechnologies Corp's market cap, and Allstate Corp pays a 1.74% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ALL | |
|---|---|---|
Market Cap | $3.33B | $63.94B |
Sector | Health | Financials |
52-Week High | $22.37 | $251.46 |
52-Week Low | $10.24 | $190.00 |
Enterprise Value | $3.19B | $72.73B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Allstate (ALL) trades at $251.46, up 0.45% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 5.49, net income margin of 17.98%, and consistent earnings beats in recent quarters. Recent news highlights Q2 2026 earnings anticipation and dividend declarations, reinforcing positive sentiment.
Outlook remains favorable given valuation discounts and earnings strength, though risks include potential hurricane impacts and market volatility. Analyst consensus leans bullish with a $249.50 price target, suggesting near-term stability with upside potential from continued operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →
